Thomson David sold $98K of MNKD

Thomson David (EVP Genl Counsel & Secretary) sold 24,109 shares of MANNKIND CORP (MNKD) at $4.05 on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomson David
Published Jul 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale details (shares, price, total value) by an executive under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited incremental information beyond confirming the transaction occurred.

03

What to watch

Traders may over-weight insider selling; without accompanying buy/sell patterns, guidance, or operational updates, the signal is weak.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-17 (same day as transaction)

Background

The article is a primary-source SEC Form 4 insider transaction for MannKind Corp (MNKD).

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind disclosed an EVP general counsel and secretary open-market sale of 24,109 shares at $4.05 on 2026-07-17 under a 10b5-1 plan.

Expected impact

Likely minimal, though it can add short-term overhang if traders interpret it as bearish.

Evidence & confidence

Form 4 insider sales are common and the article specifies a pre-arranged 10b5-1 plan, which reduces the likelihood of information asymmetry. The disclosed size is moderate relative to typical large-cap flows, and no other MNKD-specific catalyst is provided.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than a view on MNKD prospects.

Key entities

  • MANNKIND CORP

    US-listed company whose Form 4 insider sale was disclosed.

  • Thomson David

    EVP, General Counsel and Secretary who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNKDMed

MannKind (MNKD) Q3 2026 Earnings Call Transcript

MannKind (MNKD) reported Q3 2026 revenue of $101.9M, up 24% YoY. Furoscix ReadyFlow approval drove strong adoption, with 75% of prescriptions converted. Afrezza pediatric launch exceeded forecasts, with total prescriptions up 17% sequentially. The company anticipates $15M in milestones from ralinepag DPI in 2027 and key clinical data for nintedanib DPI in early 2028. MannKind closed a $50M private placement, funding a $45M CVR payment.

$MNKDMed

Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum

Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.

$MNKDHigh

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update • Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 • Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 o Furoscix ReadyFlow ™ was approved and shipments commenced mid

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.